TY - JOUR
T1 - Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease
AU - Kim, Daehong
AU - Park, Giljun
AU - Huuhtanen, Jani
AU - Lundgren, Sofie
AU - Muñoz-Calleja, Cecilia
AU - Cardeñoso, Laura
AU - Soria, Valle Gómez-García de
AU - Chen-Liang, Tzu Hua
AU - Eldfors, Samuli
AU - Ellonen, Pekka
AU - Hannula, Sari
AU - Kankainen, Matti
AU - Bruck, Oscar
AU - Kreutzman, Anna
AU - Salmenniemi, Urpu
AU - Lönnberg, Tapio
AU - Jerez, Andrés
AU - Itälä-Remes, Maija
AU - Myllymäki, Mikko
AU - Keränen, Mikko A. I.
AU - Mustjoki, Satu
PY - 2020/12
Y1 - 2020/12
N2 - Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4+ T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2 mutations. In the screening cohort (n = 134), we detect the mTOR P2229R kinase domain mutation in two additional cGvHD patients, but not in healthy or HSCT patients without cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance measurements support increased cytotoxicity of mutated CD4+ T cells. High throughput drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may contribute to aberrant T cell proliferations and persistent immune activation in cGvHD, thereby paving the way for targeted therapies.
AB - Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4+ T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2 mutations. In the screening cohort (n = 134), we detect the mTOR P2229R kinase domain mutation in two additional cGvHD patients, but not in healthy or HSCT patients without cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance measurements support increased cytotoxicity of mutated CD4+ T cells. High throughput drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may contribute to aberrant T cell proliferations and persistent immune activation in cGvHD, thereby paving the way for targeted therapies.
UR - https://doi.org/10.1038/s41467-020-16115-w
U2 - 10.1038/s41467-020-16115-w
DO - 10.1038/s41467-020-16115-w
M3 - Article
SN - 2041-1723
VL - 11
JO - Nature Communications
JF - Nature Communications
M1 - 2246
ER -